Topic: non-Hodgkin lymphoma
ADC Therapeutics has expanded its series E by $76 million, extending its runway through the end of 2020.
The agreement gives Spectrum an antibody-interferon fusion technology drug delivery platform designed to generate oncology candidates.
Injecting a vaccine into tumor sites produced remissions in mice and some lymphoma patients in a study at Mount Sinai.
Phase 2b data showed TG Therapeutics’ umbralisib partially shrank tumors in 33% and eradicated them in 19% of marginal zone lymphoma patients.
Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.
Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.
Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Longtime Cowen analyst Eric Schmidt is joining Arie Belldegrun's latest CAR-T startup, Allogene.
Epizyme's lead asset tazemetostat posted promising interim data from a phase 2 trial in follicular lymphoma.